In silico screening and docking analysis of few drugs against proteins expressed in colon cancer

Global Cancer Conference & Medicare Summit

September 15-17, 2014 Hyderabad International Convention Centre, India

Ravi Vital Kandisa, Narayana Sai Baba KV and P V Varsha

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Colon cancer claims a third rank in the list of most common cancers diagnosed in the United States. Literature findings suggest that certain proteins are highly expressed in specific type of cancer. Therefore there a need to discover drugs those are specific against specific proteins in the colon cancer. However most of the anti cancer drugs in the market are known to exhibit severe side effects. Hence new molecules with maximal efficiency of binding towards proteins expressed in colon cancer would be an advantage. Therefore in this study a novel approach has been implemented to screen the existing drugs in the market versus highly expressed proteins in colon cancer and apoptosis. This study revealed five drugs, such as Olmesartan, Verteporfin, Ritonavir, Telmisartan, Eprosartan respectively as probable anti-cancer agents based on the molecular dock scores obtained when compared with bounds ligands of each proteins.

Biography :

Ravi Vital Kandisa completed his M. Tech degree from GITAM University with specialization in Biotechnology and MBA degree from Andhra University with specialization in Human Resources Management. Currently he is doing his Ph.D. from GITAM University with the specialization in Environmental Engineering. He has attended 8 International Conferences and published papers in reputed International Journals.